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Lorenz Räber h, David Carballo f, Sebastian Carballo i, Barbara E. Stähli a, Ulf Landmesser j, 
Nicolas Rodondi k,l, François Mach f, Stephan Windecker h, Heiner C. Bucher e, 
Arnold von Eckardstein m, Thomas F. Lüscher n,o, Christian M. Matter a,n 
a Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland 
b Kerckhoff Heart and Thorax Center, Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany 
c Campus of the Justus Liebig University of Giessen, Germany 
d DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Bad Nauheim, Germany 
e Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, University of Basel, Switzerland 
f Department of Cardiology, Cardiovascular Center, University Hospital Geneva, Switzerland 
g Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland 
h Department of Cardiology, Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Switzerland 
i Department of Internal Medicine, University Hospital Geneva, Switzerland 
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A B S T R A C T   
Background and aims: Residual inflammatory risk (RIR) after acute coronary syndromes (ACS) may identify 
patients likely to benefit from anti-inflammatory therapies. 
Methods: Patients from the Special Program University Medicine ACS cohort were divided into four groups ac-
cording to level of hsCRP at baseline and after 12 months: persistently high RIR, increased RIR (first low, then 
high hsCRP), attenuated RIR (first high, then low hsCRP), or persistently low RIR. High RIR was defined as hsCRP 
≥ 2 mg/L. An independently adjudicated incident of combined adverse events was defined as the composite of 
myocardial infarction, clinically indicated coronary revascularization or cerebrovascular events. 
Results: Among 1209 patients with available hsCRP, clinical and demographic data, 295 (24.4%) patients had 
persistently high RIR (delta hsCRP median (IQR): 2.3 (− 9.9; 0.3) (mg/L) and 72 (5.96%) patients had increased 
RIR (delta hsCRP median (IQR): +2.45 (1.2; 8.35) (mg/L). A total of 390 (32.26%) patients had attenuated RIR 
(delta hsCRP median (IQR): 3.55 (− 10; − 2) (mg/L) and 452 (37.38%) patients had persistently low RIR (delta 
hsCRP median (IQR): 0.2 (− 0.6; 0.1) (mg/L). Of 90 combined adverse events, 31 (10.5%) occurred in the 
persistently high (multivariable adjusted OR: 1.71, (95% CI 1.08–2.7), p = 0.022) compared with the three other 
groups combined (increased RIR: 3 (4.2%), attenuated RIR 30 (7.7%), persistently low RIR 26 (5.8%). 
Conclusions: Persistently elevated hsCRP after ACS is found in a quarter of patients with the highest risk of 
combined adverse events. This underlines the need to perform anti-inflammatory intervention trials in RIR 
patients.   
⋆ Clinical trial registration: NCT01000701. 
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1. Introduction 
Acute coronary syndromes (ACS) constitute life-threatening mani-
festations of coronary atherosclerosis and remain associated with sub-
stantial mortality and morbidity in the subsequent 12 months [1]. 
Atherosclerosis is a lipid-driven chronic inflammatory disease of the 
arterial wall [2]. Antibody-based inhibition of interleukin-1β 
(IL-1β)-mediated inflammation reduces combined adverse events in 
patients with increased inflammatory biomarkers after myocardial 
infarction (MI) [3]. Conversely, low-dose methotrexate did neither 
impact on combined adverse events nor reduce IL-1β, IL-6 or hsCRP 
levels in patients after MI or with chronic coronary syndromes (CCS) 
with normal hsCRP levels [4]. Recently, low-dose colchicine was shown 
to reduce combined adverse events shortly after MI and in patients with 
CCS [5,6]. Therefore, the use of biomarkers involved in the pathogenesis 
of inflammation enables the identification of patients with a high 
inflammatory burden. In this process, C-reactive protein (CRP) in-
tegrates several inflammatory pathways following NLRP3 inflamma-
some assembly and activation of caspase-1 (canonical pathway) or 
caspase-4 or caspase-5 in humans (noncanonical pathway) to generate 
active IL-1β and IL-18 which induce IL-6 and CRP [7]. CRP may thus 
serve as a read-out for applying anti-inflammatory drugs targeting its 
upstream pathways, including colchicine [8]. CRP is measured by 
high-sensitivity assays (hsCRP), and a cut-off at 2 mg/L has been widely 
studied and proposed to identify patients at residual inflammatory risk 
(RIR) [9]. 
Within the large multi-center Swiss ACS cohort, we aimed to identify 
the proportion of patients with RIR based on hsCRP ≥ 2 mg/L and 
determine whether persistently high inflammation at baseline and 12 
months after ACS is associated with combined adverse events. 
Table 1 
Baseline characteristics in cohort population, non-survivors and selected study population.   
Parameters 
Cohort population Patients who died at 1 year Selected study population 
N = 2168 N = 96 N = 1209 
Age (years) n = 2168, 63.74 ± 12.44 n = 96, 74.77 ± 10.05 n = 1209, 62.42 ± 11.49 
Sex (female in %) n = 2168, 463 (21.4%) n = 96, 21 (21.9%) n = 1209, 212 (17.5%) 
Body weight (kg) n = 2139, 80.30 ± 15.12 n = 86, 76.09 ± 14.59 n = 1201, 81.00 ± 14.41 
Body Mass Index (kg/m2) n = 2137, 27.13 ± 4.34 n = 86, 26.11 ± 3.94 n = 1200, 27.21 ± 4.23 
Systolic blood pressure n = 2156, 130.59 ± 23.43 n = 95, 125.41 ± 26.01 n = 1206, 130.78 ± 22.75 
Medical history 
Diabetes mellitus n = 2168, 396 (18.3%) n = 96, 28 (29.2%) n = 1209, 187 (15.5%) 
Hypertension n = 2168, 1268 (58.5%) n = 96, 68 (70.8%) n = 1209, 690 (57.1%) 
Hypercholesterolemia n = 2166, 1348 (62.2%) n = 95, 49 (51.6%) n = 1209, 759 (62.8%) 
Current smoker n = 2133, 861 (40.4%) n = 91, 29 (31.9%) n = 1191, 475 (39.9%) 
Family history of CAD n = 2126, 547 (25.7%) n = 91, 14 (15.4%) n = 1198, 323 (27.0%) 
Chronic kidney diseasea n = 2162, 274 (12.7%) n = 96, 37 (38.5%) n = 1206, 112 (9.3%) 
History of stroke/TIA n = 2168, 82 (3.8%) n = 96, 8 (8.3%) n = 1209, 32 (2.6%) 
Previous MI n = 2166, 326 (15.1%) n = 96, 21 (21.9%) n = 1207, 169 (14.0%) 
Previous PCl n = 2167, 381 (17.6%) n = 96, 25 (26.0%) n = 1208, 191 (15.8%) 
Previous CABG n = 2168, 122 (5.6%) n = 96, 10 (10.4%) n = 1209, 58 (4.8%) 
Clinical presentation 
Unstable angina 94 (4.3%) 2 (2.1%) 54 (4.5%) 
NSTEMI 930 (42.9%) 40 (41.7%) 507 (41.9%) 
STEMI 1144 (52.8%) 54 (56.3%) 648 (53.6%) 
Index procedure 
PCI n = 2168, 1949 (89.9%) n = 96, 73 (76.0%) n = 1149, 1051 (91.5%) 
Drug-eluting stent n = 2034, 1868 (91.8%) n = 83, 67 (80.7%) n = 1149, 843 (73.4%) 
Bare-metal stent n = 2034, 1522 (74.8%) n = 83, 47 (56.6%) n = 1149, 225 (19.6%) 
PTCA only n = 2034, 376 (18.5%) n = 83, 21 (25.3%) n = 1149, 134 (11.7%) 
CABG n = 2034, 225 (11.1%) n = 83, 12 (14.5%) n = 1149, 41 (3.6%) 
Peri-procedural medications 
Unfractionated heparin n = 2164, 2071 (95.7%) n = 96, 90 (93.8%) n = 1207, 1153 (95.5%) 
LMWH n = 2167, 116 (5.4%) n = 96, 3 (3.1%) n = 1208, 77 (6.4%) 
Bivalirudin n = 2167, 96 (4.4%) n = 96, 3 (3.1%) n = 1208, 64 (5.3%) 
Glycoprotein IIb/IIIa antagonists n = 2167, 585 (27.0%) n = 96, 18 (18.8%) n = 1208, 348 (28.8%) 
Statin (yes) n = 2156, 328 (15.2%) n = 92, 62 (67.4%) n = 1204, 368 (30.56%) 
GRACE risk score 
Long-term n = 2168, 123.13 ± 26.41 n = 96, 149.83 ± 24.56 n = 1209, 120.16 ± 24.16 
hsCRP (median (IQR)) n = 1892, 2.85 (1.1, 8) n = 80, 7.6 (1.95, 27.85) n = 1209, 2.5 (1.1, 6.4) 
Measurements at 12 months 
LDL-cholesterol (mmol/L) n = 1000, 2.22 ± 0.87 Not available n = 765, 2.23 ± 0.86 
Total-cholesterol (mmol/L) n = 1009, 4.13 ± 1.02 Not available n = 766, 4.13 ± 0.99 
Triglyceride (mmol/L) n = 1001, 1.44 ± 1.06 Not available n = 766, 1.41 ± 1.09 
Statin use at 12 months 
Statin (yes) n = 1984, 1851 (93.3%) Not available n = 1207, 1143 (94.7%) 
High-intensity (yes) n = 1984, 1147 (57.8%) Not available n = 1207, 724 (60.0%) 
Depicted are counts (%) or means ± SDs. 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; LMWH, low-molecular weight heparin; MI, myocardial infarction; PCI, 
percutaneous coronary interventions; TIA, transient ischemic attack. 
a Based on creatinine-estimated glomerular filtration rate clearance of <60 mL/min/1.73 m2, using the Modification of Diet in Renal Disease (MDRD) formula. 
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2. Materials and methods 
2.1. Study design and population 
Patients with a primary diagnosis of ACS who were referred for 
coronary angiography between 2009 and 2012 were enrolled in the 
Special Program University Medicine Acute Coronary Syndromes and 
Inflammation cohort with follow-up throughout 12 months [1,10,11]. 
High RIR was defined as hsCRP ≥ 2 mg/L. Patients were divided into 
four groups based on a cut-off level of hsCRP ≥ 2 mg/L at baseline and 
12 months, respectively: persistently high RIR, increased RIR (first low, 
then high hsCRP), attenuated RIR (first high, then low hsCRP), or 
persistently low RIR as previously described in patients from a percu-
taneous coronary intervention (PCI) registry [12]. The study was 
approved by the local ethics committees. 
2.2. Clinical endpoints 
Independently adjudicated combined adverse events at 12 months 
were defined as the composite of MI, clinically indicated coronary 
revascularization, or cerebrovascular events comprising stroke or tran-
sient ischemic attacks [1,10,11]. Death was not included in combined 
adverse events as only 12-month survivors were analyzed with available 
hsCRP data at baseline and 12 months follow-up. High-intensity statin 
use comprised atorvastin 40–80 mg once daily or rosuvastatin 20–40 mg 
once daily and was ascertained at 12-month follow-up. 
2.3. Biomarker analyses 
Serum aliquots were collected at baseline from blood draws at the 
time of coronary angiography and after 12 months and stored at − 80 ◦C 
until measurement in the Zurich Core Laboratory. CRP was measured in 
serum aliquots using a high-sensitivity latex enhanced immunoturbidi-
metric assay on a Cobas c 501® autoanalyser (Roche Diagnostics, 
Mannheim, Germany) [13]. 
2.4. Global registry of acute coronary events 
The Global Registry of Acute Coronary Events (GRACE 1.0) score 
[14] was used to calculate long-term prediction of mortality and to 
assess the degree of disease severity in patients included in the current 
study. 
2.5. Statistical analysis 
Baseline characteristics are presented as means with standard de-
viations and medians for continuous variables, and categorical variables 
were shown as counts with percentages for each category of RIR. We 
used logistic regression models to evaluate possible associations be-
tween combined adverse events at 12 months follow-up for RIR groups, 
adjusted to the long-term GRACE risk score, including comprehensive 
prognostic information [14]. We used the logistic regression model as 
we have a complete follow-up of the included patients. Due to the low 
event rate for each category of RIR, we adjusted for GRACE risk score 
because the most important risk factors for ACS patients are integrated 
into this score. Two-sided p-values were reported throughout, and 
p-values smaller than 0.05 were considered statistically significant. 
Statistical analyses were performed using Stata statistical software® 
(Version 16.1, Stata Corp, and College Station, Tex). 
3. Results 
3.1. Persistently high RIR at 12 months in a quarter of ACS patients 
Among 2168 patients included in the SPUM-ACS Biomarker cohort 1, 
1209 patients had available hsCRP measurements both at baseline and 
12-month follow-up (Supplementary Fig. S1). Table 1 shows that base-
line characteristics were similar between the entire cohort and the 
current study group. In particular, the GRACE risk scores and hsCRP 
levels were similar at baseline, with no difference between groups for 
LDL-cholesterol levels and statin use at 12 months. Nearly a quarter of 
these patients after the index ACS event were in the category persistently 
high RIR, approximately 6% in the category increased RIR, whereas 
approximately a third fell in the categories attenuated RIR and persis-
tently low RIR, respectively. Table 2 shows hsCRP levels for each cate-
gory at baseline and 12 months complemented by the delta change in 
hsCRP levels during 12 months after the index ACS event. A separate 
analysis of patients who died within the 12-month follow-up (n = 96) 
showed that compared with the study population, those patients were at 
substantially higher risk for adverse events as calculated by the GRACE 
risk score and had higher hsCRP levels at baseline (Table 1). 
3.2. Persistently high RIR associated with smoking, chronic kidney 
disease, and extensive coronary artery disease and lower high-intensity 
statin use 
Baseline characteristics show that patients with persistently high RIR 
were more likely to be smokers, have chronic kidney disease, and to be 
referred to revascularization by CABG (Table 3). Conversely, patients 
with persistently low RIR were more likely to present with STEMI at the 
time of index ACS and to be treated with bivalirudin and/or glycopro-
tein IIb/IIIa antagonists. Of note, overall statin use was similar in the 
four categories at baseline. However, at 12 months, overall use of statins 
and especially the use of high-intensity statins was lower in the 
Table 2 
Prevalence of categories of persistently high, increased, attenuated or persistently low residual inflammatory risk.   
Persistently high RIR Increased RIR Attenuated RIR Persistently low RIR Overall population 
n = 295 n = 72 n = 390 n = 452 n = 1209 
BL hsCRP (mg/L) 
Mean ± SD 19.07 ± 32.01 1.32 ± 0.55 13.80 ± 27.23 0.93 ± 0.54 9.53 ± 23.41 
Median (IQR) 7.0 (4.2, 15.3) 1.4 (0.9, 1.8) 4.5 (3.0, 11.1) 0.9 (0.5, 1.4) 2.5 (1.1, 6.4) 
Min-Max 2.1–180.5 0.03–2.0 2.1–205.2 0.03–2.0 0.03–205.2 
12 months hsCRP (mg/L) 
Mean ± SD 6.88 ± 9.53 7.1 ± 7.3 1.03 ± 0.51 0.7 ± 0.45 2.7 ± 5.76 
Median (IQR) 3.9 (2.7, 7.0) 4.15 (2.5, 9.7) 1.0 (0.6, 1.4) 0.6 (0.4, 1.0) 1.1 (0.6, 2.4) 
Min-Max 2.1–99.0 2.0–44.6 0.1–2.0 0.1–1.9 0.1–99.0 
Deltaa hsCRP (mg/L) 
Mean ± SD − 12.19 ± 32.19 5.79 ± 7.35 − 12.77 ± 27.28 − 0.23 ± 0.57 − 6.84 ± 23.22 
Median (IQR) − 2.3 (− 9.9, 0.3) 2.45 (1.2, 8.35) − 3.55 (− 10, − 2) − 0.2 (− 0.6, 0.1) − 0.9 (− 3.9, 0.07) 
Min-Max − 176 to 76.9 42.9 to 5.79 − 0.1 to − 12.77 − 1.7 to 1.4 − 204.9 to 76.9  
a Delta hsCRP is defined as (hsCRP 12 months – hsCRP baseline). 
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persistently high RIR and increased RIR groups (Table 3). 
As the different clinical and hemodynamic context of STEMI and 
NSTEMI may affect hsCRP levels, we performed independent analyses of 
STEMI and NSTEMI patients. 
The persistently high RIR group remains associated with the highest 
risk for combined adverse events in both STEMI (Supplementary Table 
S1) and NSTEMI (Supplementary Table S3) compared with the three 
remaining groups. There was no major difference in median (IQR) 
hsCRP levels between patients with STEMI 2.2 (1.0, 5.75) mg/L (Sup-
plementary Table S2) and NSTEMI 3.2 (1.4, 8.5) mg/L (Supplementary 
Table S4). However, the number of events in the RIR groups is very low, 
and a separate statistical analysis will not provide reliable model co-
efficients. Thus, we refrained from modeling separately for STEMI and 
NSTEMI patients. A continuous model for hsCRP and outcome is shown 
in the Supplement (Supplementary Table S5) emphasizing the need for a 
cut-off. 
3.3. Increased combined adverse events in patients with persistently high 
RIR 
Table 4 shows the prevalence of individual components of the 
composite combined adverse events endpoint. As only survivors were 
analyzed by definition, no deaths were detected in either group. The 
highest combined adverse events rate was found in the persistently high 
RIR category. Fig. 1 shows the logistic regression analysis for associa-
tions between combined adverse events at 12 month follow-up and RIR 
groups. Patients in the persistently high RIR category had a higher event 
rate compared with the three other groups combined. Furthermore, 
direct comparison of patients in the persistently high RIR group with the 
persistently low RIR group as a reference showed a higher risk for 
combined adverse events in patients with a high inflammatory burden at 
12 months. The GRACE risk score was significantly associated with 
combined adverse events per 10 score unit increase. 
Table 3 
Baseline characteristics according to residual inflammatory risk (n = 1209).   
Parameters 
Persistently high RIR Increased RIR Attenuated RIR Persistently low RIR p-value 
n = 295 n = 72 n = 390 n = 452  
Age (years) n = 295, 62.21 ± 11.43 n = 72, 65.27 ± 11.41 n = 390, 63.14 ± 11.59 n = 452, 61.48 ± 11.38 0.028 
Sex (female in %) n = 295, 65 (22.0%) n = 72, 6 (8.3%) n = 390, 74 (19.0%) n = 452, 67 (14.8%) 0.011 
Body weight (kg) n = 293, 83.10 ± 16.63 n = 71, 80.33 ± 13.16 n = 389, 81.02 ± 13.74 n = 448, 79.71 ± 13.47 0.019 
Body Mass Index (kg/m2) n = 293, 28.35 ± 5.19 n = 71, 26.81 ± 3.81 n = 389, 27.18 ± 3.87 n = 447, 26.54 ± 3.73 <0.001 
Medical history 
Diabetes mellitus n = 295, 53 (18.0%) n = 72, 10 (13.9%) n = 390, 67 (17.2%) n = 452, 57 (12.6%) 0.155 
Hypertension n = 295, 197 (66.8%) n = 72, 46 (63.9%) n = 390, 220 (56.4%) n = 452, 227 (50.2%) <0.001 
Hypercholesterolemia n = 295, 187 (63.4%) n = 72, 43 (59.7%) n = 390, 242 (62.1%) n = 452, 287 (63.5%) 0.914 
Current smoker n = 287, 147 (51.2%) n = 71, 25 (35.2%) n = 385, 150 (39.0%) n = 448, 153 (34.2%) <0.001 
Family history of CAD n = 293, 80 (27.3%) n = 71, 14 (19.7%) n = 388, 106 (27.3%) n = 446, 123 (27.6%) 0.568 
Chronic kidney diseasea n = 295, 44 (14.9%) n = 72, 11 (15.3%) n = 389, 34 (8.7%) n = 450, 23 (5.1%) <0.001 
History of stroke/TIA n = 295, 4 (1.4%) n = 72, 2 (2.8%) n = 390, 13 (3.3%) n = 452, 13 (2.9%) 0.437 
Previous MI n = 295, 49 (16.6%) n = 72, 9 (12.5%) n = 389, 46 (11.8%) n = 451, 65 (14.4%) 0.335 
Previous PCl n = 295, 55 (18.6%) n = 72, 12 (16.7%) n = 389, 47 (12.1%) n = 452, 77 (17.0%) 0.094 
Previous CABG n = 295, 17 (5.8%) n = 72, 4 (5.6%) n = 390, 16 (4.1%) n = 452, 21 (4.6%) 0.770 
Killip class n = 294 n = 72 n = 389 n = 450  
Killip I 255 (86.7%) 63 (87.5%) 357 (91.8%) 408 (90.7%) 0.140 
Killip II 30 (10.2%) 5 (6.9%) 24 (6.2%) 35 (7.8%) 0.275 
Killip III 6 (2.0%) 2 (2.8%) 5 (1.3%) 3 (0.7%) 0.284 
Killip IV 3 (1.0%) 2 (2.8%) 3 (0.8%) 4 (0.9%) 0.462 
Clinical presentation 
Unstable angina 10 (3.4%) 6 (8.3%) 13 (3.3%) 25 (5.5%) 0.127 
NSTEMI 140 (47.5%) 34 (47.2%) 183 (46.9%) 150 (33.2%) <0.001 
STEMI 145 (49.2%) 32 (44.4%) 194 (49.7%) 277 (61.3%) <0.001 
Index procedure 
PCI n = 277, 246 (88.8%) n = 69, 64 (92.8%) n = 367, 339 (92.4%) n = 436, 402 (92.2%) 0.342 
Drug-eluting stent n = 277, 203 (73.3%) n = 69, 54 (78.3%) n = 367, 258 (70.3%) n = 436, 328 (75.2%) 0.336 
Bare-metal stent n = 277, 49 (17.7%) n = 69, 11 (15.9%) n = 367, 83 (22.6%) n = 436, 82 (18.8%) 0.318 
PTCA only n = 277, 25 (9.0%) n = 69, 6 (8.7%) n = 367, 42 (11.4%) n = 436, 61 (14.0%) 0.189 
CABG n = 277, 20 (7.2%) n = 69, 4 (5.8%) n = 367, 9 (2.5%) n = 436, 8 (1.8%) 0.001 
Peri-procedural medications 
Unfractionated heparin n = 293, 281 (95.9%) n = 72, 68 (94.4%) n = 390, 376 (96.4%) n = 452, 428 (94.7%) 0.626 
LMWH n = 294, 25 (8.5%) n = 72, 3 (4.2%) n = 390, 25 (6.4%) n = 452, 24 (5.3%) 0.298 
Bivalirudin n = 294, 11 (3.7%) n = 72, 1 (1.4%) n = 390, 19 (4.9%) n = 452, 33 (7.3%) 0.061 
Glycoprotein IIb/IIIa antagonists n = 294, 71 (24.1%) n = 72, 18 (25.0%) n = 390, 115 (29.5%) n = 452, 144 (31.9%) 0.124 
Statin (yes) n = 293, 87 (29.7%) n = 72, 21 (29.2%) n = 388, 115 (29.6%) n = 451, 145 (32.2%) 0.834 
Statin use at 12 months 
Statin (yes) n = 294, 270 (91.8%) n = 72, 66 (91.7%) n = 390, 368 (94.4%) n = 451, 439 (97.3%) 0.006 
High-intensity (yes) n = 294, 142 (48.3%) n = 72, 38 (52.8%) n = 390, 238 (61.0%) n = 451, 306 (67.8%) <0.001 
GRACE risk score 
Long-term n = 295, 119.86 ± 24.83 n = 72, 124.63 ± 24.23 n = 390, 122.16 ± 23.84 n = 452, 117.91 ± 23.82 0.028 
Depicted are counts (%) or means ± SDs. 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; LMWH, low-molecular weight heparin; MI, myocardial infarction; PCI, 
percutaneous coronary interventions; TIA, transient ischemic attack. 
Killip I: No clinical signs or symptoms of congestive heart failure; Killip II: Third heart sound, rales or radiographic evidence of CHF. 
Killip III: Pulmonary edema; Killip IV: Cardiogenic shock. 
a Based on creatinine-estimated glomerular filtration rate clearance of <60 mL/min/1.73 m2, using the Modification of Diet in Renal Disease (MDRD) formula. 
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4. Discussion 
In this prospective cohort study of ACS patients who were all 
managed according to guideline recommended interventions and 
optimal medical therapy (OMT) at 12 months after ACS [1] a quarter of 
patients had persistently increased hsCRP and [2] were more likely to 
experience combined adverse events, justifying the term residual in-
flammatory risk (RIR). 
This study represents the first analysis on the prevalence and asso-
ciation of RIR with combined adverse events at 12 months in a 
contemporary prospectively recruited all-comer ACS (NSTEMI, STEMI) 
population. Similar findings were reported from a retrospective registry 
of patients undergoing PCI for mostly CCS or unstable angina [12]. The 
course of hsCRP determined RIR, adding incremental information to the 
GRACE risk score which indeed was similar in the four risk categories. 
Prior studies in ACS patients demonstrated high proportions of patients 
with a high inflammatory burden identified by a hsCRP level ≥2 mg/L 
[15–17]. In our study, 30% of patients (persistently high RIR and 
increased RIR groups combined) had hsCRP levels ≥2 mg/L at 12 
months. The lower incidence (43% in PROVE-IT, 47% in IMPROVE-IT) 
[17] is likely attributable to a longer follow-up in the SPUM-ACS cohort 
and the wide-spread use of OMT, including high-intensity statins [18]. 
In the current study, the mean LDL-cholesterol level was 2.23 mmol/L at 
12 months in the entire cohort. The rate of overall and especially 
high-intensity statin use was lower in the persistently high and increased 
RIR groups in line with a combined residual cholesterol and inflam-
matory risk in these patients. 
Our study which followed patients for 12 months after ACS differs 
markedly from previous studies. First, the current study extends data 
from our recent publication which showed that elevated hsCRP levels by 
a single measurement at the index ACS event predict combined adverse 
events [13]. This finding is further supported by our separate analysis of 
patients in the current study who died in the first 12 months with very 
high hsCRP levels at baseline (median 7.6 mg/dL) compared with the 
current study population (2.5 mg/dL) who survived the first 12 months. 
These data are in line with the notion of ACS as a major inflammatory 
event with hsCRP levels at baseline that are commonly greater than 10 
mg/L unlike in patients with chronic coronary syndromes. 
Furthermore, it is an intriguing finding that baseline hsCRP levels 
could be low at the time of ACS but then increase to higher levels at 12 
months. Several explanations are possible [1]: Time between onset of 
acute chest pain and blood draw at baseline was variable, as was the 
type of presentation (STEMI vs. NSTEMI). However, neither the type of 
ACS nor the time interval had an impact on hsCRP level in the 
SPUM-ACS cohort [13]. [2] Progression of atherosclerotic burden in the 
coronary vasculature [3], Comorbidities developing after ACS. In sup-
port of the latter, patient characteristics associated with residual 
inflammation independent from the acute ACS event were more 
frequent in the persistently high RIR group. Indeed, our data emphasize 
the need for serial hsCRP measurements to identify patients at increased 
risk for adverse events as early as possible given that nearly half of all 
patients had low hsCRP levels (<2 mg/L) at baseline. We have previ-
ously shown that measuring hsCRP only at baseline in the SPUM-ACS 
cohort is a poor marker of future risk compared with the GRACE risk 
score, hsTnT and NT-proBNP [11]. 
Translation into the clinics of recently published anti-inflammatory 
trials using low-dose colchicine in patients shortly after MI or with 
CCS [5,6] is hampered by the lack of identified subgroups that will 
benefit the most while experiencing least side-effects. Serial hsCRP 
levels may serve as a valuable stratifying tool and it is noteworthy that 
both trials were not designed to target patients at high inflammatory 
risk. Nonetheless, as low-dose colchicine is an inexpensive and rather 
safe drug, a restrictive biomarker-guided approach is likely to exempt 
patients that may benefit from colchicine despite low-grade inflamma-
tion. The proposed biomarker-guided approach may hold the greatest 
promise for anti-inflammatory drugs with a less favorable safety profile. 
4.1. Limitations 
The study is limited to survivors with serial laboratory data avail-
able. Thus, it is unclear if hsCRP impacted on mortality. However, we 
report patient characteristics for non-survivors which show that those 
with higher hsCRP levels at baseline were at higher risk of death. Due to 
random availability of hsCRP there is no systemic bias as shown when 
comparing the entire cohort with the current study group. The lack of a 
time-dependent analysis – assessment of hsCRP at time of adverse event - 
does not allow to assess whether the events were related to a change in 
the inflammatory status over time. Serial measurements of hsCRP earlier 
than 12 months after the index ACS may enable a more rapid identifi-
cation of patients at RIR. Finally, due to the small group size (40% of the 
patients included in the analysis are missing the values for LDL- 
cholesterol), meaningful statistical analysis with respect to LDL- 
cholesterol, total cholesterol, and triglycerides, and the four RIR cate-
gories is not possible. 
4.2. Conclusions 
Residual risk for combined adverse events in ACS patients with 
persistently elevated hsCRP levels is frequent and clinical trials targeting 
inflammatory pathways involved upstream of CRP should be conducted 
in this category of high-risk patients. 
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Fig. 1. Results of the univariable (A) and multivariable (B) logistic models for RIR categories adjusted to long-term GRACE risk score for combined adverse events 
(n = 1209). 
The variables included in the long-term GRACE risk score for long-term mortality comprise age, heart rate, systolic blood pressure, serum creatinine, history of 
congestive heart failure, history of MI, elevated cardiac markers (conventional troponins as per local laboratories), ST-segment depression and no in-hospital PCI). 
GRACE: global registry of acute coronary events; combined adverse events defined as MI, clinically indicated revascularization or cerebrovascular event; RIR: 
residual inflammatory risk. 
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